CWC23 Antibody

What is CWC23 and why is it significant in cellular processes?

CWC23 is a member of the J protein family that functions as an intrinsic component of the NTR complex alongside Ntr1 and Ntr2, playing a crucial role in spliceosome disassembly. Research indicates that CWC23 interacts with the carboxyl terminus of Ntr1 and contributes to stabilizing both Ntr1 and Ntr2 proteins, which are essential for proper pre-mRNA splicing. This protein forms a stable heterotrimer with Ntr1 and Ntr2, which can further interact with Prp43 to form a tetrameric complex . The functional significance of CWC23 in splicing makes it an important target for researchers studying RNA processing mechanisms, particularly in model organisms like Saccharomyces cerevisiae where it has been extensively characterized.

What experimental evidence confirms CWC23's role in spliceosome disassembly?

Multiple lines of experimental evidence support CWC23's role in spliceosome disassembly:

• Immunodepletion studies: When CWC23 is depleted from splicing extracts using anti-CWC23 antibodies, researchers observed accumulation of intron-lariat in the splicing reaction, indicating failure in spliceosome disassembly .

• Protein interaction analysis: Immunoprecipitation experiments have demonstrated that CWC23 co-precipitates with Ntr1, Ntr2, and Prp43, but not with spliceosome components like Prp19, confirming its specific association with the disassembly machinery .

• Mutational studies: Partial loss-of-function CWC23 mutants show severe global defects in pre-mRNA splicing, with accumulation of both excised lariat introns and unspliced pre-mRNA, consistent with defects in spliceosome disassembly .

• Reconstitution experiments: Addition of affinity-purified NTR complex to CWC23-depleted extracts abolished the accumulation of intron, further supporting CWC23's functional role in the disassembly process .

What are the primary applications of CWC23 antibodies in splicing research?

CWC23 antibodies serve as essential tools in splicing research, with applications including:

• Immunoprecipitation of spliceosomal complexes: Anti-CWC23 antibodies can be used to isolate spliceosomes at specific stages of assembly/disassembly. Research protocols typically involve incubating splicing reaction mixtures with antibody-conjugated Protein A Sepharose (PAS) at 4°C, followed by multiple washes with NET-2 buffer (50 mM Tris–HCl pH7.4, 150 mM NaCl, 0.05% NP-40) .

• Immunodepletion experiments: CWC23 antibodies enable the specific removal of CWC23 and associated factors from splicing extracts to study their functional roles. This technique has revealed that depletion of CWC23 concurrently depletes Ntr1 and Ntr2, demonstrating their stoichiometric balance and interdependence .

• Western blot detection: These antibodies can be used to monitor CWC23 protein levels, localization, and interactions in various experimental contexts, including fractionation studies and protein complex purification experiments.

• Functional studies: Anti-CWC23 antibodies have been instrumental in establishing the functional association of CWC23 with the NTR complex and its role in splicing through comparative analysis of splicing activity in CWC23-depleted versus supplemented extracts.

How can CWC23 antibodies be utilized to investigate protein-protein interactions within the spliceosome?

CWC23 antibodies provide valuable tools for investigating protein-protein interactions within the spliceosome through multiple approaches:

• Co-immunoprecipitation (Co-IP): Anti-CWC23 antibodies can precipitate CWC23 along with its interacting partners, allowing researchers to identify novel interactions or confirm suspected ones. For example, Co-IP experiments with CWC23-HA tagged proteins revealed associations with Ntr1, Ntr2, and Prp43, establishing CWC23 as a component of the NTR complex .

• Sequential immunoprecipitation: This approach can help determine if CWC23 exists in multiple distinct complexes by first precipitating with anti-CWC23 antibodies, then releasing the complexes and performing a second immunoprecipitation with antibodies against suspected interacting partners.

• Glycerol gradient fractionation combined with immunoblotting: This technique has been used to demonstrate that CWC23 co-migrates with Ntr1, Ntr2, and Prp43 in a complex. After fractionating NTR complex on a 10-30% glycerol gradient, Western blotting with anti-CWC23 antibodies reveals its distribution pattern relative to other spliceosomal components .

• Two-hybrid validation: While not directly using antibodies, results from two-hybrid studies on CWC23 interactions can be confirmed using antibody-based approaches to validate the physiological relevance of detected interactions.

What controls should be included when using CWC23 antibodies in immunoprecipitation experiments?

When using CWC23 antibodies for immunoprecipitation, several critical controls should be included:

• Input sample: Always include an aliquot of the starting material to confirm the presence of the protein of interest before immunoprecipitation.

• Isotype control: Use an irrelevant antibody of the same isotype to control for non-specific binding.

• Untagged strain control: When using antibodies against tagged versions (e.g., CWC23-HA), include an untagged strain as a negative control. This approach was utilized in studies where splicing extracts from Cwc23-HA and untagged strains were compared to confirm specificity .

• Non-interacting protein control: Include a control for a protein known not to interact with CWC23 (such as Prp19, which did not co-precipitate with CWC23-HA) .

• Functional validation: After immunoprecipitation, it's advisable to test if the depleted extract shows expected functional defects. For CWC23, depletion should result in accumulation of intron-lariat in splicing assays, which can be rescued by adding back purified NTR complex .

What techniques are recommended for producing effective CWC23 antibodies for research?

Based on published research methodologies, effective production of CWC23 antibodies involves:

• Antigen design and expression: For polyclonal antibody production, full-length CWC23 or specific domains can be expressed in bacterial systems. The coding sequence for CWC23 can be cloned into expression vectors like pET-15, expressed in E. coli Rosetta strain as HIS-tagged protein, induced with IPTG (typically 1mM), and grown at lower temperatures (17°C overnight) to enhance proper folding .

• Protein purification: The expressed protein should be purified using sequential chromatography steps:

  • Initial capture using Ni-NTA affinity chromatography

  • Ion exchange chromatography (e.g., Mono-Q column)

  • Size exclusion chromatography (e.g., Sephadex-G200)

• Antibody production strategies:

  • Polyclonal antibodies: Immunize rabbits with the purified protein, followed by affinity purification of the antisera

  • Monoclonal antibodies: Standard hybridoma technology using mice immunized with the purified protein

  • Alternative approaches: Recombinant antibodies using phage display or similar technologies

• Validation: The antibodies should be validated for specificity using Western blot analysis of wild-type vs. CWC23-depleted extracts, and further confirmed by immunoprecipitation experiments comparing tagged and untagged strains .

What are the optimal conditions for using CWC23 antibodies in immunoprecipitation of spliceosomes?

Optimal conditions for CWC23 antibody use in spliceosome immunoprecipitation include:

• Antibody quantity: Research protocols indicate using approximately 10 μl of anti-CWC23 antibody per 10 μl of splicing reaction for effective immunoprecipitation . This ratio may need optimization depending on antibody affinity and concentration.

• Incubation conditions: Splicing reaction mixtures should be incubated with antibody-conjugated Protein A Sepharose (PAS) at 4°C for 1 hour to allow efficient binding while minimizing complex dissociation .

• Washing conditions: Thorough washing (typically four times with 1 ml of NET-2 buffer containing 50 mM Tris–HCl, pH7.4, 150 mM NaCl, and 0.05% NP-40) is critical to remove non-specific interactions while preserving genuine associations .

• Elution methods:

  • For RNA analysis: Direct extraction from the beads

  • For protein analysis: Elution with SDS sample buffer or appropriate peptide if using epitope-tagged versions

• Buffer conditions: Maintaining physiological salt concentrations (approximately 150 mM NaCl) and including mild detergents (0.05% NP-40) helps preserve specific interactions while reducing background.

How can researchers assess the specificity and sensitivity of CWC23 antibodies?

Assessing specificity and sensitivity of CWC23 antibodies requires multiple validation approaches:

• Western blot analysis:

  • Compare signal between wild-type extracts and those from CWC23 knockdown/knockout strains

  • Assess cross-reactivity with related J-proteins by comparing signals in extracts containing or lacking these proteins

• Immunoprecipitation validation:

  • Compare precipitated proteins from tagged (e.g., CWC23-HA) versus untagged strains

  • Verify co-precipitation of known interacting partners (Ntr1, Ntr2) and absence of unrelated proteins

• Functional validation:

  • Confirm that immunodepletion with anti-CWC23 antibodies results in expected splicing defects (accumulation of lariat-intron)

  • Demonstrate rescue of function by addition of purified NTR complex to depleted extracts

• Peptide competition assays:

  • Pre-incubate antibody with excess antigenic peptide before Western blot or immunoprecipitation

  • Specific signal should be significantly reduced or eliminated

• Cross-species reactivity assessment:

  • Test antibody performance across different species if CWC23 sequence is conserved

  • This information helps determine the breadth of research applications

How should researchers interpret CWC23 antibody data in the context of spliceosome dynamics?

Interpretation of CWC23 antibody data requires careful consideration of spliceosome dynamics:

• Temporal dynamics: CWC23 is involved primarily in spliceosome disassembly, so its detection patterns should be interpreted in the context of splicing cycle progression. Presence of CWC23 typically indicates later stages of splicing or disassembly intermediates.

• Complex composition analysis: When CWC23 is detected in immunoprecipitated complexes, researchers should examine co-precipitating factors to determine which specific spliceosomal complex has been isolated. The NTR complex components (Ntr1, Ntr2, Prp43) should co-precipitate with CWC23 .

• Functional correlations: CWC23 antibody data should be correlated with functional splicing assays. For example, accumulation of lariat-intron in CWC23-depleted extracts supports its role in spliceosome disassembly .

• Quantitative considerations: The stoichiometric relationship between CWC23, Ntr1, and Ntr2 means that relative levels detected by antibodies should be proportional. Significant deviations may indicate experimental artifacts or previously uncharacterized regulatory mechanisms .

• Context-dependent interactions: While CWC23's J domain is dispensable under normal conditions, it becomes essential when Ntr1-Prp43 interaction is compromised . This context-dependence should be considered when interpreting antibody-based interaction studies.

What are common issues when using CWC23 antibodies and how can they be addressed?

Common issues with CWC23 antibodies and their solutions include:

• High background in immunoprecipitation:

  • Solution: Increase washing stringency (more washes or slightly higher salt concentration)

  • Use cross-linked antibodies to prevent antibody leaching

  • Pre-clear lysates with Protein A/G alone before adding the antibody

• Weak or no signal in Western blots:

  • Solution: Optimize antibody concentration and incubation conditions

  • Use enhanced detection systems (high-sensitivity ECL substrates)

  • Concentrate the protein sample if CWC23 is expressed at low levels

• Non-specific bands in Western blots:

  • Solution: Optimize blocking conditions (try different blocking agents)

  • Use more stringent washing steps

  • Consider affinity-purifying the antibody against the immunizing antigen

• Poor immunoprecipitation efficiency:

  • Solution: Adjust antibody amount (research indicates ~10 μl anti-CWC23 per 10 μl splicing reaction)

  • Extend incubation time (up to overnight at 4°C)

  • Verify antibody functionality in simpler systems first

• Inconsistent results between experiments:

  • Solution: Standardize lysate preparation methods

  • Use internal controls for normalization

  • Consider using tagged versions of CWC23 with commercial anti-tag antibodies as alternative approach

How can researchers distinguish between direct and indirect interactions when using CWC23 antibodies?

Distinguishing direct from indirect interactions requires specialized approaches:

• Sequential immunoprecipitation:

  • First precipitation with anti-CWC23 antibody

  • Elution under mild conditions

  • Second precipitation with antibody against suspected direct interactor

  • Only directly interacting proteins should remain

• Cross-linking experiments:

  • Use protein cross-linkers of defined arm length prior to immunoprecipitation

  • Only proteins in close proximity will be covalently linked

  • Analyze cross-linked products by mass spectrometry

• In vitro binding assays:

  • Purify recombinant CWC23 (for example, using bacterial expression systems as described for HIS-tagged CWC23)

  • Test direct binding with purified candidate interactors

  • Compare results with immunoprecipitation data from cell extracts

• Truncation/deletion analysis:

  • Generate CWC23 truncations or domain deletions

  • Determine minimal regions required for interaction using antibodies against the remaining portions

  • Research has shown the C-terminal segment of Ntr1 is sufficient for interaction with CWC23

• Use of bridging protein nulls:

  • If interaction is suspected to be indirect via protein X, test immunoprecipitation in extracts lacking protein X

  • Loss of co-precipitation would suggest an indirect interaction

How can CWC23 antibodies be utilized to study the role of J proteins in RNA processing?

CWC23 antibodies offer unique opportunities to study J protein functions in RNA processing:

• Comparative analysis of J protein function: CWC23 is unusual among J proteins as its J domain is dispensable for its essential functions . Antibodies against CWC23 and other J proteins can be used to compare their recruitment patterns to the spliceosome and related complexes.

• Context-dependent function studies: While normally dispensable, CWC23's J domain becomes essential when Ntr1-Prp43 interaction is compromised . Antibodies can help track how CWC23's interactions change under these conditions:

  • Immunoprecipitate CWC23 from wild-type vs. Ntr1-Prp43 interaction mutants

  • Compare interacting partners using mass spectrometry

  • Analyze differences in spliceosome association patterns

• Hsp70 chaperone recruitment analysis: As J proteins typically function as cochaperones of Hsp70s, anti-CWC23 antibodies can be used to investigate whether and when CWC23 recruits Hsp70 to splicing complexes, particularly under stress conditions.

• Structural transition studies: J proteins often facilitate structural transitions. Antibodies against different CWC23 epitopes can help track conformational changes during the splicing cycle through differential accessibility.

• Evolutionary conservation analysis: By testing cross-reactivity of CWC23 antibodies with orthologs from different species, researchers can investigate the evolutionary conservation of J protein functions in RNA processing.

What are the technical challenges in studying CWC23 interactions with the spliceosome using antibody-based methods?

Studying CWC23-spliceosome interactions using antibodies presents several technical challenges:

• Transient interactions: CWC23's interactions with spliceosomal complexes may be transient during the dynamic splicing cycle. Researchers can address this by:

  • Using reversible cross-linking approaches prior to immunoprecipitation

  • Employing rapid isolation techniques with minimal washing

  • Analyzing interactions at defined stages of splicing using synchronized reactions

• Complex heterogeneity: Spliceosomes exist in multiple states and conformations. To address this:

  • Use glycerol gradient fractionation to separate different complexes before immunoprecipitation

  • Combine with specific inhibitors or ATP analogs to stall splicing at defined stages

  • Consider using spliceosome assembly in vitro on model pre-mRNA substrates

• Epitope accessibility: CWC23 epitopes may be masked within the spliceosome structure. Solutions include:

  • Use multiple antibodies targeting different regions of CWC23

  • Consider using tagged versions of CWC23 with exposed epitopes

  • Try mild detergents to partially destabilize complexes without disrupting key interactions

• Distinguishing functionally relevant from artifactual interactions: Address by:

  • Correlating antibody-detected interactions with functional splicing assays

  • Using stringent controls (isotype, untagged strains, non-interacting proteins)

  • Confirming key interactions through multiple independent methods

How might CWC23 antibodies contribute to understanding disease-associated splicing defects?

While the search results don't directly address CWC23 in disease contexts, antibodies against this protein could contribute to understanding splicing-related disorders:

• Comparative studies in disease models: CWC23 antibodies could be used to:

  • Compare CWC23 levels and interactions in healthy versus disease tissue samples

  • Examine whether CWC23-NTR complex formation is altered in splicing-related disorders

  • Investigate potential post-translational modifications of CWC23 in disease states

• Therapeutic target validation:

  • If spliceosome disassembly becomes a therapeutic target, CWC23 antibodies could help validate drug effects on NTR complex formation and function

  • Immunoprecipitation followed by activity assays could assess how potential therapeutics affect CWC23-associated complexes

• Biomarker development:

  • Changes in CWC23 levels or modifications might serve as disease biomarkers

  • Antibodies could be utilized in diagnostic immunoassays if such associations are established

• Splice variant analysis:

  • CWC23 antibodies might help investigate whether disease-associated splice variants affect spliceosome disassembly

  • Immunoprecipitation of spliceosomes from cells expressing disease-associated splice variants could reveal altered component profiles

• Stress response studies:

  • As a J protein family member, CWC23 might play roles in cellular stress responses

  • Antibodies could track CWC23 behavior under stress conditions that exacerbate splicing-related diseases

How can CWC23 antibodies be integrated with newer technologies like CRISPR-Cas9 for comprehensive splicing studies?

Integration of CWC23 antibodies with CRISPR-Cas9 technology offers powerful new research approaches:

• Genome engineering combined with antibody-based detection:

  • Generate CRISPR knock-ins of tagged CWC23 for enhanced antibody detection

  • Create conditional CWC23 mutants and use antibodies to track resulting changes in spliceosome composition

  • Introduce specific mutations in CWC23's J domain and use antibodies to assess effects on protein interactions

• Proximity labeling approaches:

  • CRISPR-mediate fusion of CWC23 with proximity labeling enzymes (BioID, APEX)

  • Use antibodies to validate proximity labeling results and confirm physiological relevance

  • Combine with splicing inhibitors to capture stage-specific interaction networks

• CWC23 variant functional analysis:

  • Generate CRISPR-edited cells expressing CWC23 variants (e.g., J domain mutants)

  • Use antibodies to compare interaction profiles of wild-type and variant CWC23

  • Correlate with splicing efficiency and specificity changes

• Live-cell imaging integration:

  • CRISPR knock-in of split fluorescent proteins into CWC23 and interacting partners

  • Use antibodies to validate observed interactions in fixed cells

  • Correlate dynamics observed in living cells with biochemically-defined complexes identified by immunoprecipitation

What methodological advances could improve CWC23 antibody applications in research?

Several methodological advances could enhance CWC23 antibody applications:

• Single-molecule approaches:

  • Develop super-resolution microscopy compatible antibodies against CWC23

  • Apply single-molecule pull-down techniques using surface-immobilized antibodies

  • Integrate with fluorescently-labeled spliceosome components to track assembly/disassembly kinetics

• Mass spectrometry enhancements:

  • Combine antibody-based purification with crosslinking mass spectrometry (CLMS) to map CWC23 interaction surfaces

  • Develop targeted proteomics assays for precise quantification of CWC23 and interacting partners

  • Use antibody-purified complexes for hydrogen-deuterium exchange mass spectrometry to study conformational dynamics

• Antibody engineering:

  • Develop recombinant antibody fragments (Fab, scFv) for improved access to sterically hindered epitopes

  • Generate split antibody complementation systems for detecting CWC23 in specific spliceosomal contexts

  • Create conformation-specific antibodies that recognize CWC23 in distinct functional states

• Microfluidic applications:

  • Develop microfluidic antibody capture systems for real-time monitoring of CWC23 interactions

  • Combine with in vitro splicing reactions to correlate CWC23 behavior with splicing progression

  • Integrate with single-cell analysis to examine cell-to-cell variation in CWC23 function